Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk M
Go back to Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk M| Geron Corp (NASDAQ: GERN) | Delayed: 1.30 -0.04 (2.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.34 | 52 Week High | $5.30 | |||
| Open | $1.32 | 52 Week Low | $1.81 | |||
| Day High | $1.35 | P/E | N/A | |||
| Day Low | $1.29 | EPS | $-0.35 | |||
| Volume | 3,510,918 | |||||
